After establishing a relationship with Harvard Medical School, TELL was selected to perform studies on speech changes in patients with intracranial electrodes suffering from epilepsy and Parkinson’s disease.

Adolfo García, CSO and co-founder of TELL, comments that “we have a long-standing connection with Harvard, and a month ago we signed an agreement to evaluate how the implantation of these electrodes could impact speech.

These patients will have electrodes implanted directly within relevant brain areas, allowing us to understand neurological correlates of speech production with a spatial and temporal resolution that far exceeds standard neuroscientific methods like MRIs or EEGs.”

“We will collaborate with the Brain Modulation Lab of MGH Neurosurgery, a well-established team at Harvard Medical School and the Massachusetts General Hospital in Boston,” García explained.

In the next phase, the joint study will evaluate the patients before surgery and after the implantation of intracranial electrodes to assess the impact of these devices on speech capabilities.

Garcia states that “initially, there’s a theoretical part to understand core cerebral aspects of speech generation, followed by a clinical component to understand how neurosurgical interventions impact speech and language skills.”

This collaboration with top-level institutions attests to the international standing of TELL and its scientific team. “We aim to build a robust database, leading to publications and clinical recommendations,” explains Adolfo.

García concludes that “beyond our scientific goals, this study strengthens TELL’s reputation and appeal for clients and investors. We look forward to the next steps in our journey of growth.”